Serum immune biomarker levels combined with hepatitis B virus infection status predict early recurrence of early-stage hepatocellular carcinoma with microvascular invasion after liver resection

• Published in: Acta chirurgica belgica 2023-11, Vol.ahead-of-print (ahead-of-print), p.1-7
• Main Authors: Wang, Xiaobo, Zhao, Yuanquan, Bai, Tao, Ye, Jiazhou, Lu, Shaolong, Wu, Feixiang, Li, Lequn, Chen, Jie
• Format: Article
• Language: English
• Subjects: Hepatocellular carcinoma; microvascular invasion; recurrence; serum immune biomarker
• ISSN: 0001-5458; 2577-0160
• DOI: 10.1080/00015458.2022.2136051

The tumor immune response plays a vital role in cancer recurrence in patients with malignancies. We aim to clarify the risk factors for early recurrence and investigate the efficacy of blood-based biomarkers to predict the risk of early recurrence in early-stage hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI) after hepatectomy. A total of 101 cases of HCC with MVI who underwent liver resection were enrolled. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors of early recurrence. We calculated the area under the receiver operating characteristic curve to evaluate the performance of the four biomarkers identified as risk factors for early recurrence. Multiple logistic regression analysis indicated that complement (C)4, cluster of differentiation (CD)4+, immunoglobulin A (IgA), and hepatitis B virus (HBV) DNA of greater than 500 IU/mL were correlated with early recurrence of HCC. The area under the curve was greater for the combination model than for the HBV DNA, CD4+, IgA, or C4 models alone. Preoperative serum CD4+, C4, IgA, and HBV DNA levels were linked with early recurrence of early-stage HCC with MVI and the combination model was of considerable predictive value for the prognosis of HCC with MVI.